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Novel thalidomide analogues display anti-angiogenic activity
independently of immunomodulatory effects
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The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties. Second generation
thalidomide analogues are distinct compounds with enhanced therapeutic potential. Although these compounds are beginning
to enter trials for the treatment of cancer there is very little information regarding the anti-angiogenic activity of these clinically
relevant compounds. Furthermore, it is not known how the various immunomodulatory activities of these compounds relate
to anti-angiogenic activity. In this study we assessed the anti-angiogenic activity of compounds from both IMiDTM and
SelCIDTM classes of analogues using a novel in vitro multicellular human assay system and the established rat aorta assay. Our
results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide. The anti-angiogenic
potency of the analogues was not related to inhibition of endothelial cell proliferation, nor their TNF-a/PDE type 4 inhibitory
properties. However, anti-migratory effects in vitro and inhibition of tumour growth in vivo was observed with the analogue
IMiD-1 (clinically known as REVIMIDTM). Our results show that anti-angiogenic activity spans both currently defined classes of
thalidomide analogue and is not related to their previously described immunomodulatory properties. Identification of the
differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.
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Angiogenesis is the formation of new blood vessels by pre-existing
endothelial cells (EC) and plays an important role in tumour
growth and progression (Folkman, 1971). The ability to attract
new vasculature from the host is thought to be a characteristic
feature of tumour cells. During vessel co-option tumours will initi-
ally exploit the host vasculature for survival and this coincides with
host vasculature regression (Griffioen and Molema, 2000). Ongoing
tumour cell growth will subsequently lead to the initiation of
angiogenesis (Holash et al, 1999). Without blood vessels tumours
cannot grow beyond a critical size or metastasise to another organ
and therefore inhibition of such processes could be a strategy for
tumour arrest (Carmeliet and Jain, 2000). Angiogenesis depends
mainly on proper activation, proliferation, adhesion, migration
and maturation of EC (Griffioen and Molema, 2000). Therefore,
inhibition of EC growth, adhesion and migration, matrix metallo-
proteinase and growth factor expression are putative anti-
angiogenic targets.
Thalidomide has previously been shown to inhibit angiogenesis
in experimental models (D’Amato et al, 1994; Kenyon et al,
1997). It has also been found inhibit microvessel formation when
co-incubated with rabbit or human microsomes, but not rat
microsomes or thalidomide alone (Bauer et al, 1998). The anti-
angiogenic activity of thalidomide is likely to be a contributing
factor for its anti-tumour effects in MM (Singhal et al, 1999)
for which it has been granted FDA approval. Furthermore, anti-
angiogenic activity has provided the rationale for its use in the
treatment of other cancers.
The side effects associated with clinically effective thalidomide
treatment has led to the design and synthesis of more potent analo-
gues with reduced toxicity. These are being characterised and
currently segregate into at least two distinct classes; Selective Cyto-
kine Inhibitory Drugs (SelCIDs), which are PDE4 inhibitors, and
Immunomodulatory Drugs (IMiDs) whose mechanism(s) of action
remain unknown. Both groups contain compounds with potent
anti-TNF-a activity although T cell costimulatory activity is limited
to the IMiD class (Corral et al, 1999; Marriott et al, 2001). However,
very little is known concerning their anti-angiogenic properties. One
SelCID analogue (CC-1069) has previously been shown to inhibit
human EC proliferation in vitro to a greater extent than thalidomide,
suggesting that it may be a more potent anti-angiogenic agent
(Moreira et al, 1999). In our study we set out to characterise the in
vitro anti-angiogenic activity of both classes of analogue to determine
whether this correlates with their immunomodulatory properties.
MATERIALS AND METHODS
Thalidomide and analogues
For the human angiogenesis assay thalidomide and various analo-
gues were dissolved in DMSO (Sigma, Kent, UK) to obtain a stock
solution of 1 mg ml71. Further dilutions were made in warm
culture medium immediately before use and 1 and 10 mg ml71
of thalidomide or analogues were administered every 48 h. Final
DMSO concentration was 0.05%. For the rat aorta assay, thalido-
mide analogues (Celgene, Warren, NJ, USA) were prepared in
Tween 80 (Sigma, Kent, UK). Dilutions were made in culture
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medium immediately before use and 1 or 10 mg ml71 of the analo-
gues were administered every 48 h. The final Tween 80
concentration was 0.025%. For in vivo treatment experiments, mice
were treated daily with 10 or 50 mg kg71 IMiD-1 with 0.5%
DMSO as vehicle (see Tumour challenge model).
Human angiogenesis kit
A commercially available human angiogenesis kit, used for the
assessment of angiogenesis in vitro (Bishop et al, 2000; Donovan
et al, 2001; Terai et al, 2001; Drinkwater et al, 2002; Osugi et al,
2002) was provided by TCS Cellworks. The assay is supplied as
growing cultures of HUVECs at the earliest stages of tubule
formation in a 24 well plate format. The assay was carried out
according to manufactures instructions with minor modifications.
In brief, 0.5 ml71 of fresh medium or medium plus drug
preparations were added to the appropriate wells. A known
angiogenic stimulator (VEGF at 5 ng ml71) and inhibitor (sura-
min at 10 mg ml71) were included as positive and negative
controls respectively in addition to medium and DMSO controls
and plates were incubated at 378C. Drug administration was
carried out every 48 h. On day 11, wells were fixed using ice
cold 70% EtOH prior to incubation (RT) for 30 min. Blocking
buffer was then added for 10 min. Endothelial cells were visua-
lised by first staining with a primary sheep anti-human for
von Willebrand factor antibody followed by a secondary donkey
anti-sheep IgG horseradish peroxidase conjugate prior to colour
development using a DAB metal substrate. The plate was washed
with ddH2O (63) and allowed to air dry overnight. Cultures
were scored manually using a 25-point Chalkley eyepiece grati-
cule (Graticules Ltd., Tonbridge, Kent, UK), previously
described as a satisfactory method of assessing tumour vascularity
(Fox et al, 1995). The extent of angiogenesis was assessed by
counting the number of points on the chalkley graticule that
landed on a tubule. The count was repeated 12 times for each
well. The term ‘graticule unit’ was assigned to this measurement
of tubule density.
Rat aorta assay
Preparation of agarose culture wells and aortic explants were
prepared as described originally Nicosia and Ottinetti, 1990, and
subsequently modified by Stevenson et al, 1998. In brief, aortic
explants were stored in DMEM/HAM F12. Agarose rings were
obtained by punching two concentric circles in the sterile agarose
gel (1.5%, w v71) with specifically designed aluminium punches.
Collagen type I from rat tail (Sigma) was dissolved overnight in
glacial acetic acid and diluted to 4.3 mg ml71 with 10% (v v71)
DMEM/HAM F12. The final collagen solution was obtained by
mixing seven volumes of 4.3 mg ml71 collagen with two volumes
NaHCO3 (11.7 mg ml
71 in DMEM/HAM F12) and one volume of
106MEM. Finally, the pH was adjusted to 7.4 with 0.1 M NaOH
using phenol red as a visual indicator. Prior to embedding of
explants in collagen gel, the bottom of each agarose well was coated
with 200 ml collagen solution and allowed to set at 378C. The wells
were then filled (further addition of 400 ml) and explants were
promptly orientated into the centre of the collagen gel. The plates
were incubated overnight with serum-free medium before group
allocation and drug treatment commenced. Drugs were prepared
as described and diluted in DMEM/HAM F12 medium to be admi-
nistered at each media change (48 h). Microvessel outgrowths in all
cultures were quantified at each media change.
Proliferation studies
Human umbilical vein endothelial cells (HUVEC) were purchased
from TCS Cellworks Ltd. (Park Leys, Botolph Claydon, Bucks,
UK) and cultured in large vessel EC basal medium and cell
growth supplement (TCS Cellworks Ltd.). The cells were passaged
between 3 – 5 times prior to use. The human endothelial-like
EA.hy926 cell line, derived from the fusion of HUVEC with the
A549 carcinoma cell line (Edgell et al, 1983), was kindly provided
by Cora-Jean Edgell (NC, USA). The cells were cultured in
DMEM with high glucose, 10% FCS and HAT. Both cell lines
were harvested from subconfluent cultures and diluted to
46104 cells ml71. Cells were seeded in 60 wells of a 96-well plate
in a volume of 100 ml71. One plate was used per test article.
Plates were incubated for 1 h at 378C and 5% CO2. Growth
factors were added at a volume of 50 ml71 with final concentra-
tions of 10 ng ml71. Thalidomide and its analogues were added
at a volume of 50 ml71 in final concentrations of 5, 10, 25,
50 mg ml71. DMSO as used as a vehicle at a final concentration
of 0.05%. Plates were incubated at 378C with 5% CO2 for 96 h.
During the last 18 h of culture 1 mCi71 of 3H-thymidine was
added per well. Plates were then stored at 7208C until analysis
using a Microbeta counter (Wallac, UK).
Wound assay for EA.hy926 cell migration
We tested IMiD-1 in the wound healing assay as described by Igura
et al, 2001. Briefly, confluent monolayers of EA.hy.926 cells in 35-
mm dishes were wounded with a rubber policeman and washed
with PBS. Then the dishes were incubated in complete DMEM
containing IMiD-1 or suramin for 16 h at 378C in a 5% CO2 incu-
bator. DMSO (0.05%) was used as control. The cell monolayers
were fixed with absolute methanol and stained with Giemsa. The
number of cells that had migrated from the edge of the wound
in each 1256500 mm area of eight randomly chosen fields was
counted. The results are presented as the average number of cells
per field.
Phosphodiesterase (PDE) type 4 assay
PDE type 4 purification from U937 cells was carried out using the
method of Hill and Mitchell (1994). PDE activity was assayed,
using a method described by Di Santo and Heaslip (1993), in
the presence of varying concentrations of thalidomide analogues.
Each data point was carried out in duplicate with activity expressed
as percentage of control. IC50 was determined from dose response
curves derived from three independent experiments.
Tumour challenge model
MF1 nude mice (nu nu71) were purchased from Harlan UK. Mice
were age and sex-matched for individual experiments. All animal
experiments have been carried out with ethical committee
approval. The ethical guidelines that were followed meet the stan-
dards set by the UKCCCR guidelines (Workman et al, 1998).
CMT93 is an epithelial-like murine rectum polypoid carcinoma cell
line with sarcomatous features derived from a C57/BL mouse
(Franks and Hemmings, 1978). Mice were challenged subcuta-
neously with 200 ml of the murine colorectal cell line CMT93
(26106 per mouse). Once the tumours reached a size of
20 mm3, the potent anti-angiogenic analogue IMiD-1 was adminis-
tered intraperitoneally daily at a concentration of 10 or
50 mg kg71. Tumours were measured every 3 – 4 days, and
volumes (in mm3) were calculated by the use of the formula (width
[mm2]6length [mm]60.52). The animals were observed daily,
and those bearing large tumours were monitored carefully for
any signs of discomfort. All mice were healthy and maintained
weight as normal throughout the study. Histological samples were
obtained using formalin-fixed, paraffin-embedded sections stained
for haematoxylin and eosin and viewed under a microscope at a
magnification of 6400.
E
xp
er
im
en
ta
l
T
h
er
ap
eu
ti
cs
Anti-angiogenic activity of thalidomide analogues
K Dredge et al
1167
ª 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1166 – 1172
Statistics
One-way analysis of variance (ANOVA) followed by a post hoc
Dunnett’s t-test was used to analyse the data. A P value 50.05
was considered to be significant. Angiogenesis data are expressed
as percentage of controls to allow intra-assay comparisons.
RESULTS
In vitro angiogenesis assays
In the human angiogenesis model, significant inhibitory effects
(P50.05) of IMiDs and SelCIDs were observed at 10 mg ml71
(Figures 1 and 2). In particular, IMiD-1 and SelCID-1 were more
potent than suramin at this concentration. Furthermore, these
analogues showed a significant reduction in tubule development
at 1 mg ml71 (P50.05). IMiD-2 and SelCID-2 were the least
potent in terms of their anti-angiogenic activity with non-signifi-
cant inhibition of tubule development at 10 mg ml71. Moreover,
only non-significant inhibition of tubule development was
observed using thalidomide. As expected the pro-angiogenic effects
of VEGF were readily apparent in this system.
In the rat aorta assay, microvessels sprouted from the edges of
explants in control groups by day 4 of culture. The number and
length of the vessels increased with time until the experiments were
terminated after 10 days of culture (Figures 1 and 3). Suramin was
found to significantly inhibit the number of microvessel
outgrowths by day 6 at a concentration of 10 mg ml71, previously
determined to be its IC50 (data not shown). The SelCID derivatives
also significantly inhibited angiogenesis in this model (Figure 3A).
SelCID-1 displayed a similar pattern to suramin at 1 mg ml71
while causing almost 100% inhibition at 10 mg ml71 (P50.05).
However, whilst SelCID-3 showed potent inhibition at both
concentrations, SelCID-2 had no effect at 1 mg ml71 and only
50% inhibition at 10 mg ml71.
The IMiD analogues also demonstrated activity as IMiD-1 (at
1 mg ml71) significantly inhibited microvessel outgrowths by day
4 (P50.05) and resulted in 100% inhibition at 10 mg ml71 (Figure
3B). In contrast, IMiD-2 had no effect at 1 mg ml71, although 90%
inhibition was observed at the 10 mg ml71 concentration by day
10. Thalidomide (at up to 50 mg ml71) did not significantly inhibit
microvessel development in the rat aorta assay (data not shown).
In some experiments, drug withdrawal after 8 days followed by
subsequent stimulation with VEGF (10 ng ml71) for a further 6
days, resulted in microvessel outgrowths 98% of control in the
1 mg ml71 groups and 76% of control in the 10 mg ml71 groups
(data not shown). This demonstrated that the analogues were
non-toxic in this system.
Endothelial cell proliferation and migration
In the proliferation studies, we found that SelCID-2 and 3 inhib-
ited bFGF and VEGF-induced proliferation (P50.05) of
HUVECs and EA.hy926 (data not shown for EA.hy926) but
SelCID-1 had no effect of proliferative responses (Figure 4). More-
over, IMiD-2 inhibited VEGF (P50.05) but not bFGF-induced
proliferation at 50 mg ml71, while thalidomide and the potent
anti-angiogenic compound IMiD-1 did not significantly inhibit
EC growth rates. Suramin did not inhibit proliferation at the
concentrations tested. However, IMiD-1 and suramin did signifi-
cantly inhibit the migration of EC (P50.05) in the wound
healing assay suggesting that both compounds may inhibit angio-
genesis by interfering with normal migratory regulation.
Tumour challenge model
In order to determine whether a thalidomide analogue with potent
anti-angiogenic activity in vitro could be beneficial in a clinical
cancer setting, we tested the most potent analogue IMiD-1, in an
in vivo tumour challenge model. Daily administration of IMiD-1
(10 or 50 mg kg71, i.p.) was found to significantly reduce the
tumour growth rates (P50.05) in nude mice and histological
examination revealed drug-treated tumours to contain vast regions
of necrotic tissue (Figure 5).
Immunomodulatory studies
The PDE4 and TNF-a inhibitory activity of thalidomide and its
analogues are presented in Table 1. This data showed that PDE4
inhibition and TNF-a inhibition are not related to the ability to
inhibit angiogenesis.
DISCUSSION
This study is the first to characterise the anti-angiogenic properties
of thalidomide analogues derived from the distinct IMiD and
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Figure 1 Illustrates the effect of a thalidomide analogue, IMiD-1 (C,F) and suramin (B,E) in comparison to their relative controls (A,D) on microvessel
outgrowths in the rat aorta assay (top row) and on tubule development in the human angiogenesis model (bottom row).
Anti-angiogenic activity of thalidomide analogues
K Dredge et al
1168
British Journal of Cancer (2002) 87(10), 1166 – 1172 ª 2002 Cancer Research UK
SelCID classes of compound. These groups of analogues have
distinct immunological effects although they both inhibit TNF-a
production by activated monocytes/macrophages. We have shown
that compounds from both groups possess potent anti-angiogenic
activity in a novel human system, confirmation of this was
obtained using the established rat aorta assay which gave similar
results. Anti-angiogenesis was observed by inhibition of microves-
sel/tubule development in a dose-dependent manner.
Results obtained using the human angiogenesis model showed
that IMiD-1 and SelCID-1 were able to significantly inhibit angio-
genesis even at the lowest concentration used (1 mg ml71). IMiD-2
significantly inhibited tubule development only at the higher
concentration (10 mg ml71), whereas at this concentration
SelCID-2 and thalidomide itself showed only non-significant inhi-
bition. Verification of this assay system is supported by our data
showing VEGF significantly increased angiogenesis in this assay
while suramin inhibited angiogenesis by approximately 50%. Sura-
min is an established anti-angiogenic agent and has been used to
treat patients with various cancers (Stein et al, 1989; Danesi et
al, 1993; Small et al, 2000). Therefore, the anti-angiogenic potency
of these compounds suggests that they may be of improved thera-
peutic value.
Thalidomide has minimal effects in the rat system, most prob-
ably due to species specificity. However, it has some effect in the
human assay, although the analogues are clearly more potent in
terms of their anti-angiogenic activity. Previously Bauer and collea-
gues (Bauer et al, 1998) have shown that thalidomide inhibited
angiogenesis in the rat aortic angiogenesis assay only when used
in combination with a microsomal preparation to allow for its
metabolism. We have noted a similar effect in this system (data
not shown). However, IMiD-1, SelCID-1 and SelCID-3 signifi-
cantly inhibited angiogenesis in the rat aorta model at very low
concentrations and in the absence of microsomes. In contrast,
IMiD-2 and SelCID-2 inhibited microvessel development to a lesser
extent (10 mg ml71). Inhibition of angiogenesis in this system was
a non-toxic effect, as drug withdrawal and subsequent stimulation
of the aortic explants with VEGF led to the development of new
microvessels (data not shown). In summary, the data generated
using the novel human assay correlate with those obtained using
the rat aorta assay. This is important in two respects; firstly, it
enables in vitro testing of putative anti-angiogenic agents prior to
their clinical assessment in vivo so that species specificity is not
an issue. Secondly, there can be more confidence that anti-angio-
genic activity previously characterised in the rat model is
applicable to the human situation.
The analogues with potent anti-angiogenic activity (e.g. IMiD-1,
SelCID-1) did not affect VEGF- or bFGF-induced HUVEC or
EA.hy926 proliferation (Figure 4). However, CC-1069 (referred to
here as SelCID-3) inhibited HUVEC proliferation at similar
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Figure 2 Inhibition of angiogenesis as demonstrated by the reduction of
tubule development following co-culture for 11 days with SelCIDs (A) or
with thalidomide or IMiDs (B) in the human angiogenesis model. The effect
of suramin or VEGF on tubule development is also shown. . *=P50.05 vs
control (Dunnett’s test).
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Figure 3 Inhibition of angiogenesis as demonstrated by the reduction in
the number of microvessels observed following co-culture with SelCIDs
(A) or with IMiDs (B) in the rat aorta angiogenesis model. The effect of
suramin on microvessel development is also shown. *=P50.05 vs control
(Dunnett’s test).
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concentrations as previously described (Moreira et al, 1999).
SelCID-2 and IMiD-2 also showed some anti-proliferative activity
but concentrations required were higher to inhibit proliferation
than anti-angiogenic activity. It is of interest to note that suramin
did not inhibit proliferation of HUVECs at the concentrations
tested, a finding consistent with previous data showing that
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Figure 4 The effect of Thd, IMiDs and SelCIDs on bFGF and VEGF-induced HUVEC proliferative responses. The data is representative of three inde-
pendent experiments.
Table 1 Demonstrates the immunomodulatory properties associated with IMiDs and SelCIDs and their effects on HUVEC proliferation and angiogenesis
PDE4 activity TNF-a activity
HUVEC inhibition
*IC50 (mg ml
71) Anti-angiogenesis
Compound IC50 (mM) IC50 (mM) bFGF VEGF Rat aorta Human model
IMiD-1 4100 0.1 450 450 3 3
IMiD-2 4100 0.02 450 48 2 2
Thalidomide 4100 190 450 450 0 1
SelCID-1 0.08 0.19 450 450 3 3
SelCID-2 2.98 1.06 20 30 2 2
SelCID-3 9.42 12.60 25 45 3 N/A
Note: approximate figures are described for IC50 values in proliferation studies. Also, angiogenesis data is ranked where 0=no effect, 1=non significant inhibition, 2=significant
inhibition at 10 mg ml71, 3=significant inhibition at 1 mg ml71. N/A=compound was not available at time of testing.
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250 mg ml71 of suramin is required to inhibit EC proliferation
(Takano et al, 1994). This indicates that the anti-angiogenic effect
observed does not correlate with antiproliferative effects on EC.
However, suramin and IMiD-1 did significantly inhibit migration
at concentrations relevant to their anti-angiogenic effects. There-
fore, our data indicates that IMiD-1 may inhibit angiogenesis
due to anti-migratory rather than anti-proliferative mechanisms.
In order to determine whether such activity would be applicable
to a clinical cancer setting, we investigated the ability of the lead
anti-angiogenic analogue IMiD-1, to inhibit tumour development
in vivo. CMT93 tumour growth rates were significantly reduced
in nude mice treated daily with IMiD-1 and these tumours were
also found to have large central necrotic areas (Figure 6). Since
there is no direct drug effect on these cells in vitro (data not
shown), we believe that the effect is mediated via inhibition of
angiogenesis. This may be due to an anti-VEGF effect since
IMiD-1 could inhibit the secretion of VEGF by CMT93 cells in
vitro (data not shown). However, it was not possible to detect
VEGF in serum from the mice.
An important observation of this study is that the anti-angio-
genic properties of IMiDs and SelCIDs cannot be attributed to
previously described functional effects. IMiDs or SelCIDs inhibit
angiogenesis but do not inhibit EC proliferation. This is also
apparent with other compounds such as thymidine phosphory-
lase whose anti-angiogenic activity is also independent of anti-
proliferative activity (Liekens et al, 2001). The anti-angiogenic
effect of IL-12 is exerted by triggering the secretion of IFN-g,
which presumably induces IP-10 and MIG (Duda et al, 2000)
and not via the inhibition of endothelial cells (Voest et al,
1998). SelCIDs are also known to potently inhibit PDE4
enzymes resulting in the inhibition of TNF-a production
(Muller et al, 1998; Marriott et al, 1998). However, we found
no correlation between the IC50s for either PDE4 inhibitory
or anti-TNF-a properties of these compounds and anti-angio-
genesis. TNF-a is weakly angiogenic in vivo (D’Amato et al,
1994). Therefore, the anti-angiogenic activity of IMiDs cannot
be attributed to their anti-TNF-a properties. Finally, IMiD-2
costimulates human T cells to a greater degree than IMiD-1
(Marriott et al, 2002) indicating mechanisms involved in T cell
activation are not involved in determining anti-angiogenic activ-
ity.
The effects of SelCIDs and IMiDs in this study provide further
evidence of the clinical potential of these novel compounds as anti-
tumour drugs. IMiD analogues have been shown to induce myelo-
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ma cell growth arrest in vitro (Hideshima et al, 2000). We have also
shown that a subgroup of SelCID analogues can induce apoptosis
in myeloma cells and also a variety of solid tumour cell types in
vitro and in vivo (Marriott et al, 2002). Since IMiD-1/REVIMIDTM
is currently under phase I/II clinical investigation in the treatment
of end stage cancer patients (Marriott et al, 2002), it is critical to
obtain as much information as possible about the anti-angiogenic
and anti-tumour capabilities of these compounds. In conclusion,
we have demonstrated potent anti-angiogenic properties within
both currently identified classes of thalidomide analogue. This is
independent of previously described immunomodulatory proper-
ties known, including TNF-a inhibition. This information adds
to our knowledge concerning these novel and promising therapeu-
tic agents and may help to target compounds to their appropriate
clinical setting.
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